FIGURE 1.
The agonist mAb reduces the cachectic effect mediated by doxorubicin treatment. Adult mice were treated with placebo (n = 8), doxorubicin (DOXO; 7 mg·kg−1, once per week up to 3 weeks; n = 10), or Doxo + mAb (5 mg·kg−1 for 24 hr before each doxorubicin treatment; n = 12). For treatment protocols, see Figure S1. (a) Body weight measurements and (b) survival rates. (c) Representative images (left panels) and volume quantification (right scatterplot) of spino‐trapezius muscles calculated by magnetic resonance analysis at Day 28 after onset of doxorubicin treatment. Bars: 3 mm. *P < .05, significantly different from placebo; # P < .05, significantly different from Doxo group